BIO 300: Phase I data

In an open-label, dose-escalation, U.S. Phase I (MARC006-025) trial in adult volunteers, BIO 300 was well tolerated. The trial evaluated single oral doses of 500, 1,000, 1,500 and 2,000 mg of BIO 300....